Goldman Sachs Group set a €111.00 ($129.07) price target on Bayer (FRA:BAYN) in a research report report published on Tuesday morning. The firm currently has a buy rating on the healthcare company’s stock.
Several other research analysts have also recently commented on BAYN. Deutsche Bank set a €137.00 ($159.30) target price on shares of Bayer and gave the stock a buy rating in a report on Friday, June 22nd. JPMorgan Chase & Co. set a €120.00 ($139.53) target price on shares of Bayer and gave the stock a buy rating in a report on Thursday, June 21st. UBS Group set a €122.00 ($141.86) price target on shares of Bayer and gave the stock a buy rating in a report on Tuesday, September 18th. DZ Bank restated a buy rating on shares of Bayer in a report on Tuesday, June 19th. Finally, Barclays set a €100.00 ($116.28) price target on shares of Bayer and gave the stock a buy rating in a report on Thursday, September 13th. Seven equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Bayer has a consensus rating of Buy and a consensus target price of €99.20 ($115.35).
Shares of BAYN opened at €77.65 ($90.29) on Tuesday. Bayer has a one year low of €91.58 ($106.49) and a one year high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Recommended Story: Investing in Growth Stocks
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.